摘要 |
Pyrimidines and triazines of formula (I), wherein R is C1-6alkyl, amino, mono- or diC1-6alkylamino; R<1> is hydrogen, C1-6alkyl, C3-6alkenyl, hydroxyC1-6alkyl or C1-6alkyloxy-C1-6alkyl; R<2> is C1-6alkyl, mono- or diC3-6cycloalkylmethyl, phenylmethyl, substituted phenylmethyl, C1-6alkyloxy- C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C3-6alkenyl; or R<1> and R<2> taken together with the nitrogen to which they are attached may form a pyrrolidinyl, morpholinyl or piperidinyl group; X is N or CR<3>; R<3> is hydrogen or C1-6alkyl; R<4> is phenyl or substituted phenyl; A is -C(=O)-, (a), or -CR<7>R<8>- wherein R<5> and R<6> each independently are hydrogen or C1-4alkyl; R<7> is hydrogen or OH, R<8> is hydrogen or C1-6alkyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing these compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).
|
申请人 |
JANSSEN PHARMACEUTICA N.V.;NEUROCRINE BIOSCIENCES INC.;WEBB, THOMAS, R.;MORAN, TERENCE, J.;MCCARTHY, JAMES, R. |
发明人 |
WEBB, THOMAS, R.;MORAN, TERENCE, J.;MCCARTHY, JAMES, R. |